BY FRIEDRICH GEIGER
FRANKFURT—Germany’s Merck KGaA suffered another setback for its cancer drug Erbitux, which in a trial failed to significantly increase the length of time advanced gastric cancer patients live without their condition worsening, the pharmaceutical and chemical company said Thursday.
The failed Phase III trial is the second for the drug in two months. In May, Merck said Erbitux showed no benefit for certain colon cancer patients. Erbitux is Merck’s …
No comments:
Post a Comment